Replies to post #141752 on Anavex Life Sciences Corp (AVXL)

[Talon38]

Whip, I stand corrected. The Clinical Trials.gov lists the two current P3's for Aducanumab as "Emerge" and "Engage"; both arms showing 1350 participants with trial completion in 2020 and subsequent read out in 2022. The participants must have MCI or be clinically diagnosed with mild Alzheimer's. Apparently, the FDA has not yet approved the trial enlargement or Clinical Trials.gov has not been updated.

One very interesting criteria for the participants. They cannot be on any blood thinners other than mild aspirin, No doubt this restriction is due to the history of brain swelling/bleeding with this drug. Consequently, it will either make the use of Aducanumab impossible or dicie for a high percentage of older people who are on blood thinners for an number of conditions like stroke, A-fib and DVT's.

Here is the "Engage" arm of the trial.

-------

https://clinicaltrials.gov/ct2/show/NCT02477800?term=Aducanumab&cond=Alzheimer+Disease&rank=2